Valink Therapeutics Secures $11.8 Million Pre‑A to Advance Next-Generation Bispecific ADC Oncology Pipeline
Valink Therapeutics, the Cambridge, Massachusetts and London‑linked biotechnology company developing next‑generation oncology therapeutics, has closed an $11.8 million Pre‑A financing round to accelerate development of its innovative pipeline of bispecific antibody‑drug conjugates (bsADCs) and complementary therapeutic modalities aimed at improving patient outcomes in cancer treatment.
The funding was led by redalpine, a pan‑European venture capital firm that focuses on transformative science and technology companies. Joining redalpine in the investment syndicate were new investors LongeVC and Oxford Science Enterprises, as well as continued support from existing backers including RV Invest, p53 Invest, and Hoxton Ventures.
Valink’s financing builds on earlier investments and reflects increasing investor confidence in its proprietary platform technologies, including a V‑gate™ discovery engine designed to expand the capabilities of traditional antibody and ADC strategies. The company was co‑founded by Arne Scheu, DPhil, who serves as CEO, and its research operations are further supported by a subsidiary in the United Kingdom, while its U.S. headquarters are based in Cambridge, Massachusetts.
The capital will be used to advance Valink’s oncology pipeline toward key preclinical development milestones, supporting the refinement and validation of bsADC candidates and other innovative biologic modalities. By integrating novel targeting strategies and advanced payload delivery mechanisms, Valink aims to overcome limitations of conventional ADCs and deliver potential first‑in‑class therapies with enhanced precision, efficacy, and safety profiles.
Bispecific ADCs represent a promising frontier in targeted cancer therapy by enabling dual engagement of tumor antigens or immune components, potentially broadening therapeutic windows and improving antitumor activity. Valink’s focus on bsADCs and related multifunctional biologics is supported by its proprietary discovery and engineering platforms, which are designed to generate highly differentiated molecules that address unmet needs in oncology.
In announcing the funding, Scheu highlighted that the financing “strengthens our position as a leader in next‑generation bispecific ADCs” and will bolster the company’s ability to bring forward clinically meaningful candidates. The round also underpins Valink’s strategic expansion in the United States, positioning the company for closer collaboration with global pharmaceutical partners and research institutions as its development programs progress.
Investor redalpine, which led the round, has a track record of backing biotech innovators and expressed enthusiasm for Valink’s discovery platform. Michael Sidler, founding partner at redalpine and board member at Valink, noted that the company’s V‑gate approach and programmable biology framework represent compelling advancements over traditional ADC technologies, unlocking potential for more effective and safer therapeutic designs.
Participation by LongeVC and Oxford Science Enterprises — both investors with deep experience in life sciences and technology commercialization — underscores broader confidence in Valink’s scientific foundation and commercial trajectory. Existing investors such as RV Invest, p53 Invest, and Hoxton Ventures, known for their support of cutting‑edge biotech ventures, also reaffirmed their commitment in this round, contributing to the company’s growth momentum.
Valink’s growth story includes a history of earlier financing and strategic development. Originally founded under the name LiliumX, the company secured initial investments to support early platform validation and leadership appointments, before rebranding and continuing to build momentum toward bsADC innovation.
The latest funding will support not only pipeline development but also the scaling of internal research capabilities and potential collaborations with partners looking to leverage Valink’s engineered biologics expertise. By advancing its proprietary discovery approaches, Valink aims to address core challenges in oncology drug development — including target engagement complexity, tumor heterogeneity, and the need for therapies with improved therapeutic indices.
As Valink progresses toward IND‑enabling studies for its lead programs and expands its U.S. presence, the infusion of funding from a strong syndicate of investors positions the company to accelerate its path from preclinical innovation to potential clinical impact. This strategic support reflects the growing interest in next‑generation ADCs as a vital class of targeted cancer therapies and underscores Valink Therapeutics’ emergence as a noteworthy player in the evolving oncology biotech landscape.
